print_label | resize_label

History

History

After AstraZeneca acquired Almirall Sofotec in 2014, the competence centre for inhalation technology was continued by AstraZeneca under the name Sofotec.

1950s

Work began in the pharmaceutical field as part of the company Degussa AG.

This pharmaceutical unit developed innovative drugs and all kinds of drug formations working alongside their own research team.

1980s

Development of metered dose inhalation products begins.

1992

Development of work on dry powder inhalers begins.

1994

Development Novolizer ® a new generation of dry powder inhalers begins.

1999

Development of a new technologically advanced dry powder inhaler begins.

2000

Launch of Novolizer ® used in the treatment of respiratory tract diseases such as asthma and chronic bronchitis.

2001

Sofotec GmbH & Co. KG was founded as a Degussa AG spin-off, taking over its expertise and intellectual property rights for inhalation products.

2006

Almirall acquired the R & D centre for inhalation and establishes the company Almirall Sofotec GmbH.

2014

AstraZeneca acquires Almirall Sofotec. Since then the unit has been known as Sofotec GmbH.

Sofotec is one of the leading pharmaceutical development companies in the field of dry powder inhalation products.